Release Summary

Dicerna announced a license agreement to use Tekmira’s proprietary lipid nanoparticle technology for delivery of DCR-PH1, Dicerna’s investigational product candidate for primary hyperoxaluria type 1.

Dicerna Pharmaceuticals, Inc.